- 美国上市药品
按申请号浏览【默认列表】
GET
fdadrugnew
请求参数
Query 参数
请求示例代码
Shell
JavaScript
Java
Swift
Go
PHP
Python
HTTP
C
C#
Objective-C
Ruby
OCaml
Dart
R
请求示例请求示例
Shell
JavaScript
Java
Swift
curl --location 'fdadrugnew'返回响应
🟢200成功
application/json
Bodyapplication/json
示例
{
"data": {
"List": {
"res": [
{
"id": 3785390741475068,
"applno": "219922",
"appltype": "仿制药",
"drugname": "PAZOPANIB HYDROCHLORIDE",
"activeingredient": "PAZOPANIB HYDROCHLORIDE",
"cname": "盐酸培唑帕尼",
"form": "TABLET;ORAL",
"route": "片剂;口服给药",
"submissionstatusdate1": "2025-09-04",
"sponsorname": "TORRENT",
"targets": "Fibroblast growth factor receptor;Mast/stem cell growth factor receptor Kit;Platelet-derived growth factor receptor;Vascular endothelial growth factor receptor",
"targets_abbr": "FGFR;KIT;PDGFR;VEGFR",
"firstgeneric": "",
"chengpishu": "",
"submissionpropertytypecode": "",
"ndc": "",
"f505b2": "",
"offexclusiity": "",
"acceleration": "",
"breakthroughtherapy": "",
"priority": "",
"fasttrack": "",
"chinesecompany": "",
"essentialmedicine": "",
"firstinclass": "",
"firstapproved": "",
"pdufa": "",
"firstcycle": "",
"submissionclasscode": "",
"strength": "EQ 400MG BASE",
"guifanshiyingzheng": "",
"referencedrug": "No",
"referencestandard": "No",
"marketingstatusid": "处方药",
"essentialmedicine_tag": "",
"nda": ""
},
{
"id": 3785390741475008,
"applno": "218755",
"appltype": "仿制药",
"drugname": "PALIPERIDONE",
"activeingredient": "PALIPERIDONE",
"cname": "帕利哌酮",
"form": "TABLET, EXTENDED RELEASE;ORAL",
"route": "缓释片剂;口服给药",
"submissionstatusdate1": "2025-09-04",
"sponsorname": "ESKAYEF",
"targets": "D(2) dopamine receptor;5-hydroxytryptamine receptor 2A;Histamine H1 receptor;Alpha-1 adrenergic receptor;5-hydroxytryptamine receptor 1D;5-hydroxytryptamine receptor 1A;D(3) dopamine receptor;5-hydroxytryptamine receptor 2C;Alpha-2 adrenergic receptor",
"targets_abbr": "DRD2;5-HT1D;5-HT1A;5-HT2C;DRD3;ADRA1;ADRA2;5-HT2A;H1R",
"firstgeneric": "",
"chengpishu": "",
"submissionpropertytypecode": "",
"ndc": "",
"f505b2": "",
"offexclusiity": "",
"acceleration": "",
"breakthroughtherapy": "",
"priority": "",
"fasttrack": "",
"chinesecompany": "",
"essentialmedicine": "",
"firstinclass": "",
"firstapproved": "",
"pdufa": "",
"firstcycle": "",
"submissionclasscode": "",
"strength": "6MG",
"guifanshiyingzheng": "",
"referencedrug": "No",
"referencestandard": "No",
"marketingstatusid": "处方药",
"essentialmedicine_tag": "",
"nda": ""
},
{
"id": 3785390741474825,
"applno": "218755",
"appltype": "仿制药",
"drugname": "PALIPERIDONE",
"activeingredient": "PALIPERIDONE",
"cname": "帕利哌酮",
"form": "TABLET, EXTENDED RELEASE;ORAL",
"route": "缓释片剂;口服给药",
"submissionstatusdate1": "2025-09-04",
"sponsorname": "ESKAYEF",
"targets": "D(2) dopamine receptor;5-hydroxytryptamine receptor 2A;Histamine H1 receptor;Alpha-1 adrenergic receptor;5-hydroxytryptamine receptor 1D;5-hydroxytryptamine receptor 1A;D(3) dopamine receptor;5-hydroxytryptamine receptor 2C;Alpha-2 adrenergic receptor",
"targets_abbr": "DRD2;5-HT1D;5-HT1A;5-HT2C;DRD3;ADRA1;ADRA2;5-HT2A;H1R",
"firstgeneric": "",
"chengpishu": "",
"submissionpropertytypecode": "",
"ndc": "",
"f505b2": "",
"offexclusiity": "",
"acceleration": "",
"breakthroughtherapy": "",
"priority": "",
"fasttrack": "",
"chinesecompany": "",
"essentialmedicine": "",
"firstinclass": "",
"firstapproved": "",
"pdufa": "",
"firstcycle": "",
"submissionclasscode": "",
"strength": "9MG",
"guifanshiyingzheng": "",
"referencedrug": "No",
"referencestandard": "No",
"marketingstatusid": "处方药",
"essentialmedicine_tag": "",
"nda": ""
},
{
"id": 3785390741474800,
"applno": "218755",
"appltype": "仿制药",
"drugname": "PALIPERIDONE",
"activeingredient": "PALIPERIDONE",
"cname": "帕利哌酮",
"form": "TABLET, EXTENDED RELEASE;ORAL",
"route": "缓释片剂;口服给药",
"submissionstatusdate1": "2025-09-04",
"sponsorname": "ESKAYEF",
"targets": "D(2) dopamine receptor;5-hydroxytryptamine receptor 2A;Histamine H1 receptor;Alpha-1 adrenergic receptor;5-hydroxytryptamine receptor 1D;5-hydroxytryptamine receptor 1A;D(3) dopamine receptor;5-hydroxytryptamine receptor 2C;Alpha-2 adrenergic receptor",
"targets_abbr": "DRD2;5-HT1D;5-HT1A;5-HT2C;DRD3;ADRA1;ADRA2;5-HT2A;H1R",
"firstgeneric": "",
"chengpishu": "",
"submissionpropertytypecode": "",
"ndc": "",
"f505b2": "",
"offexclusiity": "",
"acceleration": "",
"breakthroughtherapy": "",
"priority": "",
"fasttrack": "",
"chinesecompany": "",
"essentialmedicine": "",
"firstinclass": "",
"firstapproved": "",
"pdufa": "",
"firstcycle": "",
"submissionclasscode": "",
"strength": "3MG",
"guifanshiyingzheng": "",
"referencedrug": "No",
"referencestandard": "No",
"marketingstatusid": "处方药",
"essentialmedicine_tag": "",
"nda": ""
},
{
"id": 3785390741474731,
"applno": "218755",
"appltype": "仿制药",
"drugname": "PALIPERIDONE",
"activeingredient": "PALIPERIDONE",
"cname": "帕利哌酮",
"form": "TABLET, EXTENDED RELEASE;ORAL",
"route": "缓释片剂;口服给药",
"submissionstatusdate1": "2025-09-04",
"sponsorname": "ESKAYEF",
"targets": "D(2) dopamine receptor;5-hydroxytryptamine receptor 2A;Histamine H1 receptor;Alpha-1 adrenergic receptor;5-hydroxytryptamine receptor 1D;5-hydroxytryptamine receptor 1A;D(3) dopamine receptor;5-hydroxytryptamine receptor 2C;Alpha-2 adrenergic receptor",
"targets_abbr": "DRD2;5-HT1D;5-HT1A;5-HT2C;DRD3;ADRA1;ADRA2;5-HT2A;H1R",
"firstgeneric": "",
"chengpishu": "",
"submissionpropertytypecode": "",
"ndc": "",
"f505b2": "",
"offexclusiity": "",
"acceleration": "",
"breakthroughtherapy": "",
"priority": "",
"fasttrack": "",
"chinesecompany": "",
"essentialmedicine": "",
"firstinclass": "",
"firstapproved": "",
"pdufa": "",
"firstcycle": "",
"submissionclasscode": "",
"strength": "1.5MG",
"guifanshiyingzheng": "",
"referencedrug": "No",
"referencestandard": "No",
"marketingstatusid": "处方药",
"essentialmedicine_tag": "",
"nda": ""
},
{
"id": 3785390741474977,
"applno": "217595",
"appltype": "仿制药",
"drugname": "ZIPRASIDONE MESYLATE",
"activeingredient": "ZIPRASIDONE MESYLATE",
"cname": "甲磺酸齐拉西酮",
"form": "POWDER;INTRAMUSCULAR",
"route": "粉剂;肌肉注射",
"submissionstatusdate1": "2025-09-03",
"sponsorname": "STERISCIENCE",
"targets": "5-hydroxytryptamine receptor 2;D(2) dopamine receptor",
"targets_abbr": "5-HT2;DRD2",
"firstgeneric": "",
"chengpishu": "",
"submissionpropertytypecode": "",
"ndc": "",
"f505b2": "",
"offexclusiity": "",
"acceleration": "",
"breakthroughtherapy": "",
"priority": "",
"fasttrack": "",
"chinesecompany": "",
"essentialmedicine": "",
"firstinclass": "",
"firstapproved": "",
"pdufa": "",
"firstcycle": "",
"submissionclasscode": "",
"strength": "EQ 20MG BASE/VIAL",
"guifanshiyingzheng": "",
"referencedrug": "No",
"referencestandard": "No",
"marketingstatusid": "处方药",
"essentialmedicine_tag": "",
"nda": ""
},
{
"id": 3785390741474633,
"applno": "216432",
"appltype": "仿制药",
"drugname": "SAPROPTERIN DIHYDROCHLORIDE",
"activeingredient": "SAPROPTERIN DIHYDROCHLORIDE",
"cname": "二盐酸沙丙蝶呤",
"form": "POWDER;ORAL",
"route": "散剂;口服给药",
"submissionstatusdate1": "2025-09-03",
"sponsorname": "HOPEWELL PHARMA",
"targets": "Phenylalanine-4-hydroxylase",
"targets_abbr": "PAH",
"firstgeneric": "",
"chengpishu": "",
"submissionpropertytypecode": "",
"ndc": "",
"f505b2": "",
"offexclusiity": "",
"acceleration": "",
"breakthroughtherapy": "",
"priority": "",
"fasttrack": "",
"chinesecompany": "",
"essentialmedicine": "",
"firstinclass": "",
"firstapproved": "",
"pdufa": "",
"firstcycle": "",
"submissionclasscode": "",
"strength": "100MG/PACKET",
"guifanshiyingzheng": "",
"referencedrug": "No",
"referencestandard": "No",
"marketingstatusid": "处方药",
"essentialmedicine_tag": "",
"nda": ""
},
{
"id": 3785390741474594,
"applno": "216432",
"appltype": "仿制药",
"drugname": "SAPROPTERIN DIHYDROCHLORIDE",
"activeingredient": "SAPROPTERIN DIHYDROCHLORIDE",
"cname": "二盐酸沙丙蝶呤",
"form": "POWDER;ORAL",
"route": "散剂;口服给药",
"submissionstatusdate1": "2025-09-03",
"sponsorname": "HOPEWELL PHARMA",
"targets": "Phenylalanine-4-hydroxylase",
"targets_abbr": "PAH",
"firstgeneric": "",
"chengpishu": "",
"submissionpropertytypecode": "",
"ndc": "",
"f505b2": "",
"offexclusiity": "",
"acceleration": "",
"breakthroughtherapy": "",
"priority": "",
"fasttrack": "",
"chinesecompany": "",
"essentialmedicine": "",
"firstinclass": "",
"firstapproved": "",
"pdufa": "",
"firstcycle": "",
"submissionclasscode": "",
"strength": "500MG/PACKET",
"guifanshiyingzheng": "",
"referencedrug": "No",
"referencestandard": "No",
"marketingstatusid": "处方药",
"essentialmedicine_tag": "",
"nda": ""
},
{
"id": 3785390741475304,
"applno": "219170",
"appltype": "仿制药",
"drugname": "MILRINONE LACTATE IN DEXTROSE 5%",
"activeingredient": "MILRINONE LACTATE",
"cname": "乳酸米力农",
"form": "INJECTABLE;INJECTION",
"route": "注射剂;注射给药",
"submissionstatusdate1": "2025-09-02",
"sponsorname": "CAPLIN",
"targets": "Phosphodiesterase 3;Phosphodiesterase 4",
"targets_abbr": "PDE3;PDE4",
"firstgeneric": "",
"chengpishu": "",
"submissionpropertytypecode": "",
"ndc": "",
"f505b2": "",
"offexclusiity": "",
"acceleration": "",
"breakthroughtherapy": "",
"priority": "",
"fasttrack": "",
"chinesecompany": "",
"essentialmedicine": "",
"firstinclass": "",
"firstapproved": "",
"pdufa": "",
"firstcycle": "",
"submissionclasscode": "",
"strength": "EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)",
"guifanshiyingzheng": "",
"referencedrug": "No",
"referencestandard": "No",
"marketingstatusid": "处方药",
"essentialmedicine_tag": "",
"nda": ""
},
{
"id": 3785390741475254,
"applno": "218586",
"appltype": "仿制药",
"drugname": "RISPERIDONE",
"activeingredient": "RISPERIDONE",
"cname": "利培酮",
"form": "INJECTABLE;INTRAMUSCULAR",
"route": "注射剂;肌肉注射",
"submissionstatusdate1": "2025-09-02",
"sponsorname": "AMNEAL",
"targets": "D(2) dopamine receptor;5-hydroxytryptamine receptor 2A;Histamine H1 receptor;Alpha-1 adrenergic receptor;Alpha-2 adrenergic receptor",
"targets_abbr": "DRD2;ADRA1;ADRA2;5-HT2A;H1R",
"firstgeneric": "",
"chengpishu": "",
"submissionpropertytypecode": "",
"ndc": "",
"f505b2": "",
"offexclusiity": "",
"acceleration": "",
"breakthroughtherapy": "",
"priority": "",
"fasttrack": "",
"chinesecompany": "",
"essentialmedicine": "",
"firstinclass": "",
"firstapproved": "",
"pdufa": "",
"firstcycle": "",
"submissionclasscode": "",
"strength": "25MG/VIAL",
"guifanshiyingzheng": "",
"referencedrug": "No",
"referencestandard": "No",
"marketingstatusid": "处方药",
"essentialmedicine_tag": "",
"nda": ""
},
{
"id": 3785390741475242,
"applno": "218832",
"appltype": "仿制药",
"drugname": "PITOLISANT",
"activeingredient": "PITOLISANT",
"cname": "盐酸替洛利生",
"form": "TABLET",
"route": "片剂",
"submissionstatusdate1": "2025-09-02",
"sponsorname": "ANNORA PHARMA PRIVATE LIMITED",
"targets": "Histamine H3 receptor",
"targets_abbr": "HH3R",
"firstgeneric": "",
"chengpishu": "",
"submissionpropertytypecode": "",
"ndc": "",
"f505b2": "",
"offexclusiity": "",
"acceleration": "",
"breakthroughtherapy": "",
"priority": "",
"fasttrack": "",
"chinesecompany": "",
"essentialmedicine": "",
"firstinclass": "",
"firstapproved": "",
"pdufa": "",
"firstcycle": "",
"submissionclasscode": "",
"strength": "17.8MG",
"guifanshiyingzheng": "猝倒症;发作性睡病日间嗜睡",
"referencedrug": "No",
"referencestandard": "No",
"marketingstatusid": "暂定批准",
"essentialmedicine_tag": "",
"nda": ""
},
{
"id": 3785390741475241,
"applno": "211220",
"appltype": "仿制药",
"drugname": "RISPERIDONE",
"activeingredient": "RISPERIDONE",
"cname": "利培酮",
"form": "INJECTABLE;INTRAMUSCULAR",
"route": "注射剂;肌肉注射",
"submissionstatusdate1": "2025-09-02",
"sponsorname": "NANOMI",
"targets": "D(2) dopamine receptor;5-hydroxytryptamine receptor 2A;Histamine H1 receptor;Alpha-1 adrenergic receptor;Alpha-2 adrenergic receptor",
"targets_abbr": "DRD2;ADRA1;ADRA2;5-HT2A;H1R",
"firstgeneric": "",
"chengpishu": "",
"submissionpropertytypecode": "",
"ndc": "",
"f505b2": "",
"offexclusiity": "",
"acceleration": "",
"breakthroughtherapy": "",
"priority": "",
"fasttrack": "",
"chinesecompany": "",
"essentialmedicine": "",
"firstinclass": "",
"firstapproved": "",
"pdufa": "",
"firstcycle": "",
"submissionclasscode": "",
"strength": "50MG/VIAL",
"guifanshiyingzheng": "",
"referencedrug": "No",
"referencestandard": "No",
"marketingstatusid": "处方药",
"essentialmedicine_tag": "",
"nda": ""
},
{
"id": 3785390741475122,
"applno": "218586",
"appltype": "仿制药",
"drugname": "RISPERIDONE",
"activeingredient": "RISPERIDONE",
"cname": "利培酮",
"form": "INJECTABLE;INTRAMUSCULAR",
"route": "注射剂;肌肉注射",
"submissionstatusdate1": "2025-09-02",
"sponsorname": "AMNEAL",
"targets": "D(2) dopamine receptor;5-hydroxytryptamine receptor 2A;Histamine H1 receptor;Alpha-1 adrenergic receptor;Alpha-2 adrenergic receptor",
"targets_abbr": "DRD2;ADRA1;ADRA2;5-HT2A;H1R",
"firstgeneric": "",
"chengpishu": "",
"submissionpropertytypecode": "",
"ndc": "",
"f505b2": "",
"offexclusiity": "",
"acceleration": "",
"breakthroughtherapy": "",
"priority": "",
"fasttrack": "",
"chinesecompany": "",
"essentialmedicine": "",
"firstinclass": "",
"firstapproved": "",
"pdufa": "",
"firstcycle": "",
"submissionclasscode": "",
"strength": "37.5MG/VIAL",
"guifanshiyingzheng": "",
"referencedrug": "No",
"referencestandard": "No",
"marketingstatusid": "处方药",
"essentialmedicine_tag": "",
"nda": ""
},
{
"id": 3785390741475078,
"applno": "219564",
"appltype": "仿制药",
"drugname": "TOPIRAMATE",
"activeingredient": "TOPIRAMATE",
"cname": "托吡酯",
"form": "CAPSULE, EXTENDED RELEASE;ORAL",
"route": "缓释胶囊;口服给药",
"submissionstatusdate1": "2025-09-02",
"sponsorname": "AJANTA PHARMA LTD",
"targets": "Carbonic anhydrase 2;Glutamate receptor ionotropic, kainate 1",
"targets_abbr": "GluK1;CA-II",
"firstgeneric": "",
"chengpishu": "",
"submissionpropertytypecode": "",
"ndc": "",
"f505b2": "",
"offexclusiity": "",
"acceleration": "",
"breakthroughtherapy": "",
"priority": "",
"fasttrack": "",
"chinesecompany": "",
"essentialmedicine": "",
"firstinclass": "",
"firstapproved": "",
"pdufa": "",
"firstcycle": "",
"submissionclasscode": "",
"strength": "150MG",
"guifanshiyingzheng": "",
"referencedrug": "No",
"referencestandard": "No",
"marketingstatusid": "处方药",
"essentialmedicine_tag": "",
"nda": ""
},
{
"id": 3785390741475062,
"applno": "219541",
"appltype": "仿制药",
"drugname": "TASIMELTEON",
"activeingredient": "TASIMELTEON",
"cname": "他司美琼",
"form": "SUSPENSION",
"route": "",
"submissionstatusdate1": "2025-09-02",
"sponsorname": "MSN LABORATORIES PRIVATE LTD",
"targets": "Melatonin receptor type 1B;Melatonin receptor type 1",
"targets_abbr": "MTNR1B;MT1",
"firstgeneric": "",
"chengpishu": "",
"submissionpropertytypecode": "",
"ndc": "",
"f505b2": "",
"offexclusiity": "",
"acceleration": "",
"breakthroughtherapy": "",
"priority": "",
"fasttrack": "",
"chinesecompany": "",
"essentialmedicine": "",
"firstinclass": "",
"firstapproved": "",
"pdufa": "",
"firstcycle": "",
"submissionclasscode": "",
"strength": "4MG/1ML",
"guifanshiyingzheng": "",
"referencedrug": "No",
"referencestandard": "No",
"marketingstatusid": "暂定批准",
"essentialmedicine_tag": "",
"nda": ""
},
{
"id": 3785390741474995,
"applno": "219564",
"appltype": "仿制药",
"drugname": "TOPIRAMATE",
"activeingredient": "TOPIRAMATE",
"cname": "托吡酯",
"form": "CAPSULE, EXTENDED RELEASE;ORAL",
"route": "缓释胶囊;口服给药",
"submissionstatusdate1": "2025-09-02",
"sponsorname": "AJANTA PHARMA LTD",
"targets": "Carbonic anhydrase 2;Glutamate receptor ionotropic, kainate 1",
"targets_abbr": "GluK1;CA-II",
"firstgeneric": "",
"chengpishu": "",
"submissionpropertytypecode": "",
"ndc": "",
"f505b2": "",
"offexclusiity": "",
"acceleration": "",
"breakthroughtherapy": "",
"priority": "",
"fasttrack": "",
"chinesecompany": "",
"essentialmedicine": "",
"firstinclass": "",
"firstapproved": "",
"pdufa": "",
"firstcycle": "",
"submissionclasscode": "",
"strength": "100MG",
"guifanshiyingzheng": "",
"referencedrug": "No",
"referencestandard": "No",
"marketingstatusid": "处方药",
"essentialmedicine_tag": "",
"nda": ""
},
{
"id": 3785390741474968,
"applno": "218586",
"appltype": "仿制药",
"drugname": "RISPERIDONE",
"activeingredient": "RISPERIDONE",
"cname": "利培酮",
"form": "INJECTABLE;INTRAMUSCULAR",
"route": "注射剂;肌肉注射",
"submissionstatusdate1": "2025-09-02",
"sponsorname": "AMNEAL",
"targets": "D(2) dopamine receptor;5-hydroxytryptamine receptor 2A;Histamine H1 receptor;Alpha-1 adrenergic receptor;Alpha-2 adrenergic receptor",
"targets_abbr": "DRD2;ADRA1;ADRA2;5-HT2A;H1R",
"firstgeneric": "",
"chengpishu": "",
"submissionpropertytypecode": "",
"ndc": "",
"f505b2": "",
"offexclusiity": "",
"acceleration": "",
"breakthroughtherapy": "",
"priority": "",
"fasttrack": "",
"chinesecompany": "",
"essentialmedicine": "",
"firstinclass": "",
"firstapproved": "",
"pdufa": "",
"firstcycle": "",
"submissionclasscode": "",
"strength": "50MG/VIAL",
"guifanshiyingzheng": "",
"referencedrug": "No",
"referencestandard": "No",
"marketingstatusid": "处方药",
"essentialmedicine_tag": "",
"nda": ""
},
{
"id": 3785390741474882,
"applno": "211220",
"appltype": "仿制药",
"drugname": "RISPERIDONE",
"activeingredient": "RISPERIDONE",
"cname": "利培酮",
"form": "INJECTABLE;INTRAMUSCULAR",
"route": "注射剂;肌肉注射",
"submissionstatusdate1": "2025-09-02",
"sponsorname": "NANOMI",
"targets": "D(2) dopamine receptor;5-hydroxytryptamine receptor 2A;Histamine H1 receptor;Alpha-1 adrenergic receptor;Alpha-2 adrenergic receptor",
"targets_abbr": "DRD2;ADRA1;ADRA2;5-HT2A;H1R",
"firstgeneric": "",
"chengpishu": "",
"submissionpropertytypecode": "",
"ndc": "",
"f505b2": "",
"offexclusiity": "",
"acceleration": "",
"breakthroughtherapy": "",
"priority": "",
"fasttrack": "",
"chinesecompany": "",
"essentialmedicine": "",
"firstinclass": "",
"firstapproved": "",
"pdufa": "",
"firstcycle": "",
"submissionclasscode": "",
"strength": "25MG/VIAL",
"guifanshiyingzheng": "",
"referencedrug": "No",
"referencestandard": "No",
"marketingstatusid": "处方药",
"essentialmedicine_tag": "",
"nda": ""
},
{
"id": 3785390741474860,
"applno": "219170",
"appltype": "仿制药",
"drugname": "MILRINONE LACTATE IN DEXTROSE 5%",
"activeingredient": "MILRINONE LACTATE",
"cname": "乳酸米力农",
"form": "INJECTABLE;INJECTION",
"route": "注射剂;注射给药",
"submissionstatusdate1": "2025-09-02",
"sponsorname": "CAPLIN",
"targets": "Phosphodiesterase 3;Phosphodiesterase 4",
"targets_abbr": "PDE3;PDE4",
"firstgeneric": "",
"chengpishu": "",
"submissionpropertytypecode": "",
"ndc": "",
"f505b2": "",
"offexclusiity": "",
"acceleration": "",
"breakthroughtherapy": "",
"priority": "",
"fasttrack": "",
"chinesecompany": "",
"essentialmedicine": "",
"firstinclass": "",
"firstapproved": "",
"pdufa": "",
"firstcycle": "",
"submissionclasscode": "",
"strength": "EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)",
"guifanshiyingzheng": "",
"referencedrug": "No",
"referencestandard": "No",
"marketingstatusid": "处方药",
"essentialmedicine_tag": "",
"nda": ""
},
{
"id": 3785390741474834,
"applno": "219564",
"appltype": "仿制药",
"drugname": "TOPIRAMATE",
"activeingredient": "TOPIRAMATE",
"cname": "托吡酯",
"form": "CAPSULE, EXTENDED RELEASE;ORAL",
"route": "缓释胶囊;口服给药",
"submissionstatusdate1": "2025-09-02",
"sponsorname": "AJANTA PHARMA LTD",
"targets": "Carbonic anhydrase 2;Glutamate receptor ionotropic, kainate 1",
"targets_abbr": "GluK1;CA-II",
"firstgeneric": "",
"chengpishu": "",
"submissionpropertytypecode": "",
"ndc": "",
"f505b2": "",
"offexclusiity": "",
"acceleration": "",
"breakthroughtherapy": "",
"priority": "",
"fasttrack": "",
"chinesecompany": "",
"essentialmedicine": "",
"firstinclass": "",
"firstapproved": "",
"pdufa": "",
"firstcycle": "",
"submissionclasscode": "",
"strength": "50MG",
"guifanshiyingzheng": "",
"referencedrug": "No",
"referencestandard": "No",
"marketingstatusid": "处方药",
"essentialmedicine_tag": "",
"nda": ""
}
],
"count": 50154,
"page": 1
}
},
"code": 200,
"msg": "成功"
}修改于 2025-11-18 03:17:16